Patent · US Active

Cancer treatment combinations

US11654193B2 · kind B2 · utility

0Cited by

160References

13Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Thomas J. Kipps · San Diego, US
Liguang Chen · San Diego, US
Bing Cui · San Diego, US

Key dates

Filing date	May 8, 2020
Grant date	May 23, 2023
Priority date	—
Expiry date	Feb 25, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.